LM Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

LM Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50	Closed	-$153	–	256
2023 Q4	$153	Buy	+50	New	+$151	﹤0.01%	722

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LM Advisors's AVIR Position: Q1 2024 in Review

LM Advisors sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 50 shares — an estimated $153 sold.

LM Advisors first reported a position in AVIR in Q4 2023 and held it in 1 quarter. The position peaked at $153 in Q4 2023. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

LM Advisors reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 50 Atea Pharmaceuticals shares in Q1 2024, an estimated $153.
LM Advisors first reported a position in Atea Pharmaceuticals in Q4 2023 and held it in 1 quarter.
LM Advisors's Atea Pharmaceuticals position peaked at $153 in Q4 2023.
113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.